Guggenheim Maintains Buy on Genmab, Lowers Price Target to $40
Genmab A/S -3.41% Post
Genmab A/S GMAB | 28.30 28.30 | -3.41% 0.00% Post |
Guggenheim analyst Michael Schmidt maintains Genmab (NASDAQ:
GMAB) with a Buy and lowers the price target from $45 to $40.